BSX · News · 20260825N

Guidance / Outlook

BOSTON SCIENTIFIC CORP · 2026-08-25 · Importance 47 · Surprise 60

Boston Scientific has made recent guidance cuts, according to TD Cowen's commentary. The revisions led analysts to reduce their revenue-growth estimates for 2027. Boston Scientific nevertheless exceeded second-quarter revenue and EPS expectations, while analyst concerns remained focused on specific product lines.

Key facts

• Recent guidance cuts and cautious remarks have led to reduced revenue growth estimates for 2027. source
• TD Cowen reiterated a Buy rating for Boston Scientific and maintained a $56.00 price target. source